Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RARE 2: Talazoparib and Temozolomide in Advanced Rare Cancers
NCT05142241Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jul 2022
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of talazoparib, temozolomide, sponsored by National Cancer Institute. Started Jul 2022; status: active, not recruiting.
02
Drugs
talazoparibtemozolomide
Beyond the preview
Go deeper on NCT05142241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05142241.